![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C26H29N5O4S |
Molar mass | 507.61 g·mol−1 |
3D model ( JSmol) | |
|
SRT-1460 is a drug in development by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. It has similar activity in animal studies to the known SIRT1 activator resveratrol, but is closer in potency to SRT-1720. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. [1] However, the claim that SRT1460 is a SIRT1 activator has been questioned [2] and further defended. [3]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C26H29N5O4S |
Molar mass | 507.61 g·mol−1 |
3D model ( JSmol) | |
|
SRT-1460 is a drug in development by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. It has similar activity in animal studies to the known SIRT1 activator resveratrol, but is closer in potency to SRT-1720. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. [1] However, the claim that SRT1460 is a SIRT1 activator has been questioned [2] and further defended. [3]